{"entity":{"id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","aka":["APEX-06"],"tldr":"A phase 2 trial of ICP-248 in mantle cell lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) is a phase 2 interventional study registered as NCT07082686 by Beijing InnoCare Pharma Tech Co., Ltd., with 75 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: ICP-248. Conditions listed: Relapsed or Refractory Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07082686","url":"https://clinicaltrials.gov/study/NCT07082686"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["icp-248"],"companies":["innocare"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07082686","phase":"2","setting":"A Single-arm, Multi-center, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","started":"2025-08-21","startedType":"actual","enrolled":75,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07082686/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/"}],"company":[{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/"}]}}